|
Galectin Therapeutics Inc (NASDAQ: GALT) |
|
Galectin Therapeutics Inc
GALT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Galectin Therapeutics Inc's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.5 %
Galectin Therapeutics Inc net loss decreased from $-11 millions, to $-10 millions in first quarter of 2025,
• More on GALT's Growth
|
|
Galectin Therapeutics Inc realized a net loss in trailing twelve months.
Galectin Therapeutics Inc realized cash reduction of $ -0.26 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on GALT's Valuation
|
|
|
|
|
Galectin Therapeutics Inc realized net loss in trailing twelve months.
Galectin Therapeutics Inc realized cash outflow of $ -0.26per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on GALT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com